Development of a Urinary Screening Method, a Urinary Quantitative Confirmatory Method and Metabolic Profiling of the Semi-Synthetic Cannabinoid Hexahydrocannabinol in Humans Using UPLC-MS-QToF and UHPLC-MS/MS

Hegyiné Kemenes Klaudia; E. Hidvegi; G. Süvegh

doi:10.34257/GJMRBVOL24IS1PG35

Authors

Hegyiné Kemenes Klaudia
E. Hidvegi
G. Süvegh

Keywords:

Abstract

Abstract not found

Downloads

Article PDF

How to Cite

Development of a Urinary Screening Method, a Urinary Quantitative Confirmatory Method and Metabolic Profiling of the Semi-Synthetic Cannabinoid Hexahydrocannabinol in Humans Using UPLC-MS-QToF and UHPLC-MS/MS. (2024). Global Journal of Medical Research, 24(B1), 35-63. https://doi.org/10.34257/GJMRBVOL24IS1PG35

Download Citation

References

(1961) Unknown Title.

(2022) World Drug Report 2022.

P Squires (2009) The Prosecution of Drug Users in Europe: Insights Series 5: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA): Office for Official Publications of the European Communities, Luxembourg, 2002 ISBN 92-9168-124-5. 18(1), 122-124.

István Ujváry (2023) Hexahydrocannabinol and closely related semi‐synthetic cannabinoids: A comprehensive review. 16(2), 127-161.

(2022) EU Early Warning System formal notification.

Robert Archer, Donald Boyd, Paul Demarco, Irene Tyminski, Norman Allinger (1970) Structural studies of cannabinoids. Theoretical and proton magnetic resonance analysis. 92(17), 5200-5206.

Patricia Reggio, Kaylar Greer, Stephanie Cox (1989) The importance of the orientation of the C9 substituent to cannabinoid activity. 32(7), 1630-1635.

Silvia Graziano, Maria Varì, Simona Pichini, Francesco Busardo, Tommaso Cassano, Annagiulia Di Trana (2023) Hexahydrocannabinol Pharmacology, Toxicology, and Analysis: The First Evidence for a Recent New Psychoactive Substance. 21(12), 2424-2430.

K Kemenes, E Hidvégi, L Szabó, Á Kerner, G Süvegh (2023) Metabolism of the Synthetic Cathinone Alpha-Pyrrolidinoisohexanophenone in Humans Using UHPLC--MS-QToF. 47(3), 253-262.

Maria Andersson, Xingxing Diao, Ariane Wohlfarth, Karl Scheidweiler, Marilyn Huestis (2016) Metabolic profiling of new synthetic cannabinoids AMB and 5F‐AMB by human hepatocyte and liver microsome incubations and high‐resolution mass spectrometry. 30(8), 1067-1078.

Xingxing Diao, Zhiyu Ma, Haidong Wang, Dafang Zhong, Yifan Zhang, Jing Jin, Yaxin Fan, Xiaoyan Chen (2013) Simultaneous quantitation of 3-n-butylphthalide (NBP) and its four major metabolites in human plasma by LC-MS/MS using deuterated internal standards. 78-79(79), 19-26.

David Fabregat-Safont, Marie Mardal, Juan Sancho, Félix Hernández, Kristian Linnet, María Ibáñez (2020) Metabolic profiling of four synthetic stimulants, including the novel indanyl-cathinone 5-PPDi, after human hepatocyte incubation. 10(2), 147-156.

J Beers, L Authement, A, K Isoherranen, N Jackson, K, D (2023) Cytosolic Enzymes Generate Cannabinoid Metabolites 7-Carboxycannabidiol and 11-Nor-9-carboxytetrahydrocannabinol. 14(5), 614-620.

Willi Schirmer, Volker Auwärter, Julia Kaudewitz, Stefan Schürch, Wolfgang Weinmann (2023) Identification of human hexahydrocannabinol metabolites in urine. 29(5-6), 326-337.

W Schirmer (2023) XXVIII international meeting of The International Association of Forensic Toxicologists (TIAFT). 57(3), 337.

J Carlier, S Malaca (2023) Origin of the Different Binding Affinities of (9R)- and (9S)Hexahydrocannabinol (HHC) for the CB1 and CB2 Cannabinoid Receptors. 13.

F Faro, A Tini (2023) Development and validation of a quantitative LC-MS/MS method for the stereoisomers 9R-and 9S-hexahydrocannabinol in blood, oral fluid and urine: application to authentic human samples. 43.

G Bambagiotti, M Fede (2023) Hexahydrocannabinol (HHC) concentrations in blood, oral fluid and urine following a single.